The effects of N-butylscopolamine on bowel uptake: an F-FDG PET study

Nuclear Medicine Communications

Volumn 29, Issue 1, 2008, Pages 11-16

  Emmott, Jennifer ^a   Sanghera, Bal ^a   Chambers, Jane ^a   Wong, Wai Lup ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Artefacts; Buscopan; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SCOPOLAMINE BUTYL BROMIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; ARTIFACT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; RANK SUM TEST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMAGE ENHANCEMENT; INTESTINE; INTESTINE ABSORPTION; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BUTYLSCOPOLAMMONIUM BROMIDE; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; INTESTINAL ABSORPTION; INTESTINES; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 39149119652     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f1d706     Document Type: Article

References (14)

1. Warburg O. The Metabolism of Tumours (translated by F. Dickens). London: Constable; 1930.
2. Shreeve PD, Anzai YA, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiograhics 1999; 19:61-77.
3. Cook GJR, Fogelman I, Maisey M. Normal physiological and benign pathological variants of FDG-PET scanning: potential for error. Semin Nucl Med 1996; 26:308-314.
4. Miraldi F, Vesselle H, Faulhaber P, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med 1998; 23:3-7.
5. Bowman W, Rand M. Textbook of Pharmacology. 2nd edn. Oxford: Blackwell Scientific; 1980.
6. Lee JR. Routine use of hyoscine N butylbromide (Buscopan) in double contrast barium enema examinations. Clin Radiol 1982; 33:273-276.
7. British Medical Association and the Royal Pharmaceutical Society. British National Formulary, September 2003. London: BMA; 2003.
8. Neal MJ. Pharmacology at a Glance, 2nd edn. London: Blackwell Science; 1992.
9. Bova JG, Jurdi RA, Bennett RF. Antispasmodic drugs to reduce discomfort and colonic spasm during barium enemas: comparison of oral hyoscyamine, i.v. glucagon, and no drug. Am J Roentgenol 1993; 161:965-968.
10. Massoud TF, Nolan DJ. Dose reduction of hyoscine-N-butylbromide for double-contrast barium meal examinations - a prospective randomized study. Clin Radiol 1992; 46:340-343.
11. Yasuda S, Takahashi W, Takagi S, Fujii H, Ide M, Shohtsu A. Factors influencing physiological uptake in the intestine. Tokai J Exp Clin Med 1998; 23:241-244.
12. Stahl A, Weber WA, Avril N, Schwaiger M. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin 2000; 39:241-245.
13. Jadvar H, Schambye M, Regitze B, Segall G. Effect of atropine and sincalide on the intestinal uptake of F18 fluorodeoxyglucose. Clin Nucl Med 1999; 24:965-967.
14. Fumiyasu Y, Nakada K, Zhao S, Satoh M, Asaka M, Tamaki N. Gastrointestinal uptake of FDG after N-butylscopolamine or omeprazole treatment in the rat. Ann Nucl Med 2004; 18:637-640.